General description
Complement receptor type 1 (UniProt: P17927; also known as C3b/C4b receptor, CD35) is encoded by the CR1 (also known as C3BR) gene (Gene ID: 1378) in human. CD35 is a single-pass type I membrane glycoprotein of the receptors of complement activation (RCA) family. It is synthesized with a signal peptide (aa 1-42), which is subsequently cleaved off to generate the mature form that contains a long extracellular domain (aa 42-1971) , a transmembrane domain (aa 1972-1996), and a cytoplasmic domain (aa 1997-2039). It contains 30 Sushi domains. Its expression has been reported on erythrocytes, a subset of T-cells, mature B cells, follicular dendritic cells, monocytes, and granulocytes. It serves as a membrane immune adherence receptor that plays a critical role in the capture and clearance of complement -opsonized pathogens by erythrocytes and monocytes/macrophages. Its ligands include C3b, iC3b, and C4b fragments of C3 and C4 proteins. CD35 also acts as an inhibitor of spontaneous complement activation by impairing the formation and function of the alternative and classical pathways C3/C5 convertases, and by serving as a cofactor for the cleavage of C3b to iC3b, C3c, and C3d, C3g, and C4b, C4c, and C4d by factor I. It also plays a role in immune regulation by contributing, upon ligand binding, to the generation of regulatory T cells from activated helper T cells and inn maintaining a balance between normal and pathological B-cell activation. (Ref.: Kremlitzka, M., et al. (2013). Int. Immunol. 25(1); 25-33; Schifferli, JA., et al. (1988). J. Immunol. 140(3); 899-904); Hogg, N., et al. (1984). Eur . J . Immunol. 14(3); 236-243).
Immunogen
Acute monocytic leukemia cells and normal blood monocytes.
Application
Quality Control Testing
Evaluated by Flow Cytometry in Human peripheral blood mononuclear cells (PBMC).
Flow Cytometry Analysis: 1.0 µg of this antibody detected CD35 in one million Human peripheral blood mononuclear cells (PBMC).
Tested Applications
Flow Cytometry Analysis: A representative lot detected CD35 in Flow Cytometry applications (Mahmoudi, R., et al. (2015). Neurobiol Aging. 36(4):1766.e5-1766.e12).
Radioimmunoassay: A representative lot detected CD35 in Radioimmunoassay applications (Hogg, N., et al.(1984). Eur J Immunol. 14(3):236-43).
Inhibition Analysis: A representative lot detected CD35 in Inhibition applications (Hogg, N., et al.(1984). Eur J Immunol. 14(3):236-43).
Dot Blot Analysis: A representative lot detected CD35 in Dot Blot applications (Nickells, M., et al. (1998). Clin Exp Immunol. 112(1):27-33).
Immunofluorescence Analysis: A representative lot detected CD35 in Immunofluorescence applications (Hogg, N., et al.(1984). Eur J Immunol. 14(3):236-43).
ELISA Analysis: A representative lot detected CD35 in ELISA applications (Nickells, M., et al. (1998). Clin Exp Immunol. 112(1):27-33; Fonseca, M.I., et al. (2016). PLoS One. 11(2):e0149792).
Western Blotting Analysis: A representative lot detected CD35 in Western Blotting applications (Mahmoudi, R., et al. (2015). Neurobiol Aging. 36(4):1766.e5-1766.e12).
Immunohistochemistry Applications: A representative lot detected CD35 in Immunohistochemistry applications (Hogg, N., et al.(1984). Eur J Immunol. 14(3):236-43; Fonseca, M.I., et al. (2016). PLoS One. 11(2):e0149792).
Immunocytochemistry Analysis: A representative lot detected CD35 in Immunocytochemistry applications (Fonseca, M.I., et al. (2016). PLoS One. 11(2):e0149792).
Immunoprecipitation Analysis: A representative lot detected CD35 in Immunoprecipitation applications (Hogg, N., et al.(1984). Eur J Immunol.;14(3):236-43; Nickells, M., et al. (1998). Clin Exp Immunol. 112(1):27-33; Fonseca, M.I., et al. (2016). PLoS One. 11(2):e0149792).
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
Biochem/physiol Actions
Clone E11 is a mouse monoclonal antibody that detects CD35. It targets an epitope within the extracellular domain.
Physical form
Purified mouse monoclonal antibody IgG1 in PBS without azide.
Preparation Note
1.0 mg/mL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
Store at -10°C to -25°C. Handling Recommendations: Upon receipt and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
